SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: luckydog885/7/2025 9:01:01 AM
2 Recommendations

Recommended By
erippetoe
jhcimmu

  Read Replies (2) of 63284
 
SRPT this morning:

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics(SRPT) with a Overweight and lowers the price target from $182 to $113.

Needham analyst Gil Blum maintains Sarepta Therapeutics(SRPT) with a Buy and lowers the price target from $183 to $125.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext